<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">Cigna Group (NYSE: CI) has announced that it will <a aria-label="not pursue a merger with Humana (opens in a new tab)" href="https://www.reuters.com/markets/deals/cigna-says-it-will-not-pursue-combination-with-humana-2024-11-11/" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">not pursue a merger with Humana (NYSE: HUM</a><a href="https://www.reuters.com/markets/deals/cigna-says-it-will-not-pursue-combination-with-humana-2024-11-11/" target="_blank" aria-label="not pursue a merger with Humana (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">)</a>, a decision that has impacted the stock prices of both companies. <br><br>The announcement came shortly after <a href="https://tokenist.com/tesla-stock-jumps-14-as-trump-announced-2024-election-winner/" rel="noopener noreferrer nofollow" class="deco-link">Donald Trump’s re-election as the U.S. president</a>, a political development that had previously fueled speculation about the merger’s potential to pass antitrust scrutiny. The decision to halt merger talks was described as “unusual” by industry analysts, suggesting strategic motives behind Cigna’s move to alleviate pressure on its stock.</p>
<h3 id="cigna-to-not-pursue-humana-merger">Cigna to Not Pursue Humana Merger</h3>
<p>In the wake of the announcement, Cigna’s stock saw a significant increase, rising nearly 8% in <a href="https://tokenist.com/investing/how-to-trade-after-hours/" rel="noopener noreferrer nofollow" class="deco-link">premarket trading</a> today. This surge reflects investor confidence in Cigna’s strategic direction and its commitment to maintaining established merger and acquisition criteria. On the other hand, Humana’s shares fell more than 5% before the bell, indicating investor disappointment and uncertainty about Humana’s future prospects without the merger.</p>
<p>Cigna has reiterated its focus on strategic alignment, financial attractiveness, and a high probability of closure in its merger and acquisition activities. The company is currently in the process of selling its Medicare Advantage business and plans to repurchase shares in the fourth quarter and in 2025. These moves are part of Cigna’s broader strategy to enhance shareholder value and streamline its operations.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="ci-stock-brief">CI Stock Brief</h3>
<p>Analyzing Cigna’s recent stock performance, the company’s shares opened at $342.52 on November 11, 2024, showing a substantial increase from the previous close of $319.77 on November 8, 2024. The stock reached a day high of $347.62 and a day low of $339.81, reflecting a <a href="https://tokenist.com/investing/what-is-beta-in-stocks/" rel="noopener noreferrer nofollow" class="deco-link">volatile trading session</a>. Over the past year, Cigna’s stock has fluctuated between a low of $253.95 and a high of $370.83, indicating a robust performance within the healthcare sector.<br><br>At the time of writing (11:08 AM EST), Cigna was trading at $343.50 (up 7.42%) and Humana was trading at $275.61 (down 4.36%).</p>
<p>Cigna’s financial metrics highlight its strong market position. With a market capitalization of $95.64 billion, a dividend yield of 1.75%, and a <a href="https://tokenist.com/investing/p-e-ratio/" rel="noopener noreferrer nofollow" class="deco-link">forward P/E ratio</a> of 10.89, the company is well-positioned for future growth. <br><br>Analysts have given Cigna a “buy” recommendation, with a target mean price of $396.35, suggesting potential for further stock price appreciation.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/cignas-stock-surges-after-dropping-humana-merger-plans/">Cigna’s Stock Surges After Dropping Humana Merger Plans</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Cigna’s Stock Surges After Dropping Humana Merger Plans

Table of Contents

Tokenist

Other articles published on Nov 11, 2024

Altcoin Steals the Spotlight with BULLRUN100 Bonus: Solana’s $200 Ascent & AVAX’s Recovery Mission!

Solana price hits 2+ year high — Is a new SOL all-time high on the way?

Bitcoin Price Just Broke a New ATH Above $82K

Near Protocol Launches Ambitious AI Project

3 Altcoins Hint at Explosive Price Growth Following the US Presidential Election

Altcoin’s New Offer ‘BULLRUN100 Bonus’ Doubles Your Holdings – TRON’s 270M User Milestone & AAVE’...

Join our free newsletter for daily crypto updates!